Other substances

Bromhexine hydrochloride

A mucolytic agent and a TMPRSS2 inhibitor.

Phase of research

Potential treatment - clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

3
 Supporting references
0
 Contradictory references
3
 AI-suggested references
2
 Clinical trials

General information

Bromhexine hydrochloride is a secretolytic/mucolytic agent (NCIt) and a TMPRSS2 inhibitor (Lucas et al., 2014).

Bromhexine (hydrochloride) on DrugBank
Bromhexine hydrochloride on PubChem
Bromhexine (hydrochloride) on Wikipedia

Marketed as

AMIOREL; BISOLMED; BISOLVON; FLUIBRON

 

Structure image - Bromhexine hydrochloride

CN(CC1=C(C(=CC(=C1)Br)Br)N)C2CCCCC2.Cl

Supporting references

Link Tested on Impact factor Notes Publication date
Alpha 1 Antitrypsin is an Inhibitor of the SARS-CoV2-Priming Protease TMPRSS2
TMPRSS2 Preprint 		HEK-293T cell culture

inhibited TMPRSS2 proteolytic function

 Oct/07/2020
Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID‐19: An Open‐label Randomized Controlled Pilot Study
TMPRSS2 Small molecule Randomized controlled open trial Moderate severity Mild severity 		Patients 3.37

Improvement (statistically not significant) in chest computer tomography findings, oxygen therapy need and the discharge rate within 20 days. Sample size: 12 + 6 control. Dosage: 32 mg twice daily for 14 days.


 Sep/03/2020
Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial
Small molecule Randomized controlled open trial 		Patients 3.19

A significantly lower rate of ICU admission, intubation, and 28-day mortality in the bromhexine treatment group compared to the control group. Sample size: 39 + 39 control. Dosage: 8 mg three times a day for 2 weeks.


 Jul/19/2020

AI-suggested references

Link Publication date
Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach.
May/26/2021
Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID-19: An Open-Label Randomized Controlled Pilot Study
Oct/10/2020
Bromhexine Hydrochloride Prophylaxis of COVID-19 for Medical Personnel: A Randomized Open-Label Study
Oct/30/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT04405999 Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease Completed Phase 4 May/14/2020 Aug/31/2020
  • Alternative id - 05-20-02-С
  • Interventions - Drug: Bromhexine Hydrochloride
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Almazov National Medical Research Centre, Saint Petersburg, Russian Federation
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 50
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Polymerase chain reaction (PCR)|Time to symptoms|Time to positive PCR|Number of cases|Case severity|Drug tolerance
NCT04273763 Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19) Active, not recruiting Not Applicable Feb/16/2020 Jun/01/2020
  • Alternative id - 2019NCP1.0
  • Interventions - Drug: Bromhexine Hydrochloride Tablets|Drug: Arbidol Hydrochloride Granules|Drug: Recombinant Human Interferon α2b Spray
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - The Second AffIliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
  • Study designs - Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 18
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Time to clinical recovery after treatment|Rate of aggravation|Clinical remission rate|Dynamic changes of oxygenation index|Time to cure|rate to cure|Time to defervescence|Time to cough remission|Time to dyspnea remission|Days of supplemental oxygenation|Rate of patients with requring supplemental oxygen|Rate of patients with mechanical ventilation|Time of negative COVID-19 nucleic acid results|Rate of negative COVID-19 nucleic acid results|Rate of ICU admission|28-day mortality
Export (.csv)